Advertisement

PentaVision

Retinal Physician

Article | 2026 ASRS Meeting

Lessons From the ARCHER Trial

Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.

By: Margaret Chang, MD
Retinal Physician July 19, 2026
5 Key Takeaways

  • 1

    The ARCHER trial focused on the effects of vonaprument on vision loss in patients with geographic atrophy.

  • 2

    Vonaprument targets C1q, a key trigger in the classical complement cascade associated with neurodegenerative diseases.

  • 3

    Patients with baseline vision between 20/40 and 20/100 were identified as having the highest risk for 15-letter vision loss.

  • 4

    Subfoveal lesions were found to increase the risk of 15-letter vision loss compared to nonsubfoveal lesions.

  • 5

    Findings from the ARCHER trial informed the design of the ongoing phase 3 ARCHER II study, expected to report results later this year.